Therapeutic Areas of Interest

 Diabetic Peripheral Neuropathy

The World Health Organization estimates that more than 171 million people have diabetes worldwide, a figure that is expected to rise to 366 million by 2030.

One major complication of diabetes is diabetic peripheral neuropathy, a painful nerve disorder that affects at least half of those who have had diabetes for 25 years or more. A market research report released in 2004 estimated the worldwide market for peripheral neuropathy (which includes diabetic peripheral neuropathy) treatments would reach $1 billion by 2012, yet to date, few treatments exist for this painful and debilitating condition.

Quigley Pharma’s compound QR-333 is a unique topical compound designed to reduce the oxidative stress that contributes to peripheral diabetic neuropathy, relieving pain and other symptoms.